Lyon, September 27, 2018 – Theranexus, an innovative biopharmaceutical company specializing in the treatment of neurological diseases, and a pioneer in the development of drug candidates affecting the interaction between neurons and glial cells, today announces its first half 2018 results.
Franck Mouthon, Chairman, CEO and co-founder of Theranexus, made the following comments: "For Theranexus, 2018 was marked by a step-up in its development, including the launch of clinical trials for its drug candidates THN101 and THN102. The first half was also marked by the continuation of our phase II clinical trial for narcolepsy, the launch of our Parkinson's disease clinical trial in (with the first enlisted participant announced in July) and the pharmacokinetic study of glial modulator THN01, present in THN101 and THN201. The amount of expenditure, mainly for the various clinical trials, is perfectly in line with the targets announced during the Company's initial public offering in October 2017."
First half 2018 financial results
|€000 (French GAAP)||H1-2018||H1-2017|
|Other purchases and external charges||2,024||535|
|Wages and social security charges||992||377|
|Amortization and depreciation of fixed assets||21||12|
|Other operating expenses||10||3|
|Net operating income/(expenses)||(2,947)||(868)|
|Net financial income/(expense)||0||(71)|
The Company's half-year report for the first half of 2018 will be available on its website on 29, September 2018.
Other purchases and external expenses increased during the period to €2,024 K up from €535 K in the first half of 2017. This increase was driven by the impact of new clinical trials, and specifically the phase II Parkinson's trial.
The increase in wages and social security charges, which rose from €377 K in the first half of 2017 to €992 K in the first half of 2018, reflects the Company's overall expansion:
- Expanded clinical department to conduct the various clinical trials in parallel
- Creation of a Finance Department prior to the Company's initial public offering (IPO)
- Strengthening the R&D and Business Development functions
Accordingly, operating expenses increased from €868 K in the first half of 2017 to €2,947 K in 2018.
The net financial expense, primarily including interest on loans and repayable advances, returned to break-even in the first half of 2018, up from a €71 K expense in the first half of 2017, the Company having repaid the majority of its borrowings following its IPO in October 2017.
After recognition of €893 K in tax income, mainly comprising the Research Tax Credit, the net expense amounted to €2,054 K for the first half of 2018, compared to a €710 K expense in the first half of 2017.
With a controlled cash outflow of €3,281 K during the period, cash at June 30, 2018 amounted to €14,945 K, compared to €18,226 K at December 31, 2017, providing the Company with a clear outlook for its clinical development plan.
Financial and Administrative Director
ACTUS finance & communication
Caroline Lesage / Théo Martin
+33 (0)1 53 67 36 79 / +33 (0)1 53 67 36 75
+ 33 (0)6 07 76 82 83